February 6, 2015
Eisai disclosed on February 5 details of its option rights for US-based Biogen Idec’s investigational Alzheimer’s disease (AD) treatment BIIB037, an anti-amyloid beta antibody, and the anti-tau monoclonal antibody under the collaboration deal for the next generation of AD treatments...read more